STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires $63,277.60 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock in a transaction dated Thursday, March 27th. The shares were bought at an average cost of $17.48 per share, with a total value of $63,277.60. Following the completion of the purchase, the insider now owns 12,424,944 shares in the company, valued at approximately $217,188,021.12. This represents a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was bought at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were bought at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The shares were acquired at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was bought at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

Shares of NASDAQ:STAA opened at $17.79 on Friday. STAAR Surgical has a 52-week low of $13.50 and a 52-week high of $52.68. The business’s 50 day simple moving average is $19.43 and its two-hundred day simple moving average is $25.23. The firm has a market cap of $877.49 million, a P/E ratio of -43.39 and a beta of 0.66.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, StockNews.com cut shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, STAAR Surgical presently has a consensus rating of “Hold” and a consensus price target of $25.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Resona Asset Management Co. Ltd. purchased a new position in shares of STAAR Surgical during the 4th quarter valued at $36,411,000. Vanguard Group Inc. boosted its holdings in shares of STAAR Surgical by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares in the last quarter. Yunqi Capital Ltd raised its stake in shares of STAAR Surgical by 48.9% during the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock worth $18,640,000 after acquiring an additional 252,113 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after buying an additional 172,779 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in STAAR Surgical by 25.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock valued at $20,728,000 after buying an additional 171,046 shares during the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.